Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, P. R. China.
Mol Pharm. 2010 Feb 1;7(1):105-15. doi: 10.1021/mp900151k.
Despite remarkable progress in the research of both viral and nonviral gene delivery vectors, the drawbacks in each delivery system have limited their clinical applications. Therefore, one of the concepts for developing novel vectors is to overcome the limitations of individual vectors by combining them. In the current study, adenoviral vectors were formulated with anionic liposomes to protect them from neutralizing antibodies and to improve their transduction efficiency in Coxsackievirus-adenovirus receptor (CAR) deficient cells. A calcium-induced phase change method was applied to encapsulate adenovirus 5 (Ad5) into anionic liposomes to formulate the complexes of Ad5 and anionic liposomes (Ad5-AL). Meanwhile, the complexes of Ad5 and cationic liposomes (Ad5-CL) were also prepared as controls. LacZ gene expression in CAR overexpressing cells (A549) and CAR deficient cells (CHO and MDCK) was measured by either qualitative or quantitative detection. Confocal laser scanning microscopy was performed to determine intracellular location of Ad5 after their infection. Human sera with a high titer of antiadenovirus antibody were used to assess the neutralizing antibody protection ability of the complexed vectors. Accompanying the enhanced gene expression, a high ability to introduce Ad5 into cytoplasm and nucleus mediated by Ad5-AL was also observed in CAR deficient cells. Additionally, antibody neutralizing assay indicated that neutralizing serum inhibited naked Ad5 and Ad5-CL at rather higher dilution than Ad5-AL, which demonstrated Ad5-AL was more capable of protecting Ad5 from neutralizing than Ad5-CL. In conclusion, anionic liposomes prepared by the calcium-induced phase change method could significantly enhance the transduction ability of Ad5 in CAR deficient cells.
尽管在病毒和非病毒基因传递载体的研究方面取得了显著进展,但每种传递系统的缺点限制了它们的临床应用。因此,开发新型载体的概念之一是通过结合它们来克服单个载体的局限性。在本研究中,腺病毒载体与阴离子脂质体结合,以保护它们免受中和抗体的影响,并提高其在柯萨奇病毒-腺病毒受体(CAR)缺陷细胞中的转导效率。采用钙诱导相变法将腺病毒 5(Ad5)包封到阴离子脂质体中,以制备 Ad5 和阴离子脂质体(Ad5-AL)复合物。同时,还制备了 Ad5 和阳离子脂质体(Ad5-CL)复合物作为对照。通过定性或定量检测来测量 CAR 过表达细胞(A549)和 CAR 缺陷细胞(CHO 和 MDCK)中的 LacZ 基因表达。通过共焦激光扫描显微镜来确定感染后 Ad5 的细胞内位置。使用高滴度抗腺病毒抗体的人血清来评估复合载体的中和抗体保护能力。伴随增强的基因表达,在 CAR 缺陷细胞中观察到 Ad5-AL 介导的 Ad5 向细胞质和细胞核的高效导入。此外,抗体中和试验表明,中和血清对裸 Ad5 和 Ad5-CL 的抑制作用比 Ad5-AL 高得多,这表明 Ad5-AL 比 Ad5-CL 更能保护 Ad5 免受中和。总之,钙诱导相变法制备的阴离子脂质体可显著增强 Ad5 在 CAR 缺陷细胞中的转导能力。